Lund, Sweden, 08.00 am CET, 25 April 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q1 2019 Interim Report on Thursday 2 May 2019 at 08.00 am CET.
The Company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English.
The dial-in numbers for the conference call are:
UK: +44 3333009270
SE: +46 850558365
US: +1 8335268382
The presentation will be webcasted and can be accessed from the following
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46(0) 46 286 53 70
The information was submitted for publication, through the agency of the contact person set out above, at 08.00 am CET on 25 April 2019.